Cogent (COGT) Climbs 13.05% on August 5

Equities Staff  |

Cogent Biosciences Inc (NASDAQ: COGT) has gained $1.39 (13.05%) and sits at $12.00, as of 11:51:35 est on August 5.

383,420 shares have traded hands.

The Company is up 6.29% over the last 5 days and shares advanced 16.52% over the last 30 days.

Cogent anticipates its next earnings on 2022-08-15.

For technical charts, analysis, and more on Cogent visit the company profile.

About Cogent Biosciences Inc

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA.

To get more information on Cogent Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Cogent Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

These Stocks are Sending a Signal (like Amazon in 2008)
It Isn’t a Recession Until This Group of Economists Says So
What You Should Know About Europe's Energy Wars
Meatless Meats and Smokeless Smokes
Mixed Wireless Recovery at AT&T, Verizon, T-Mobile: Jeff Kagan
The Strong Dollar Is a Problem for Stocks



Market Movers

Sponsored Financial Content